Ibnsina Pharma Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Mohamed Mohsen Mahgoub
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 3.7yrs |
| CEO ownership | n/a |
| Management average tenure | no data |
| Board average tenure | 7.2yrs |
Recent management updates
Recent updates
CEO
Mohamed Mohsen Mahgoub
3.7yrs
Tenure
Mr. Mohamed Mohsen Mohamed Mahgoub serves as Vice Chairman and Chief Executive Officer at Ibn Sina Pharma (S.A.E) since April 2021. He served as Executive Chairman until April 2021 and has been Director at...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Vice Chairman & CEO | 7.2yrs | no data | no data | |
| Co-CEO & Director | 7.2yrs | no data | 4.91% EGP 330.8m | |
| Co-CEO & Director | 7.2yrs | no data | 5.91% EGP 397.7m | |
| Director | 7.2yrs | no data | 8.12% EGP 546.6m | |
| Director | 7.2yrs | no data | no data | |
| Director | 7.2yrs | no data | no data | |
| Director | 7.2yrs | no data | 2.31% EGP 155.8m | |
| Non-Executive Chairman | 7.2yrs | no data | 0.15% EGP 10.2m | |
| Director | no data | no data | 4.61% EGP 310.4m | |
| Director | no data | no data | no data |
7.2yrs
Average Tenure
Experienced Board: ISPH's board of directors are considered experienced (7.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/27 00:58 |
| End of Day Share Price | 2024/12/26 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Ibnsina Pharma is covered by 9 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Neveen Ghonima | Beltone Financial |
| Aly Adel | Beltone Financial |
| Alia El Mehelmy | CI Capital Research |